




BENEFITS OF NATIVE CT-II™



Characteristics of collagen

Collagen works as the body's glue by holding everything together and is responsible for healing the body, providing a protective coating for vital organs, producing new cells and improving strength, flexibility and stability.

Collagen is the primary structural protein for the body's connective tissue, cartilage, tendons and ligaments which helps knee joints function properly.

Collagen levels in the body begin to decrease after the age of 40, which can lead to weakened cartilage causing joint pain and inflammation.

Type II collagen

Type II collagen is a major collagen found in cartilage.

Chicken cartilage collagen contains the sulfates chondroitin and glucosamine, both of which are essential for assisting with cartilage support in joints.

Native CT-II™ is derived from chicken cartilage and is a standardised form of Undenatured Type II collagen.

Dosage: 40mg once a day

Potential Areas for Use

- Osteoarthritis
- Post-surgery pain
- Back Pain
- loint Pain

Differentiated value¹

Undenatured Type II collagen	Glucosamine
Small, easy to swallow pill	Large pill
Taken once a day	Taken 2 to 3 times a day
Daily 40mg dose	Daily 1500mg dose
Greatest decrease on WOMAC scale ²	Moderate decrease on WOMAC scale

¹ Lugo, J.P., et al. (2016). Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicentre randomized, double-blind, placebo-controlled study. Nutrition Journal, 15(14). doi:10.1186/s12937-016-0130-8

² Western Ontario McMaster Universities Osteoarthritis Index


³ Visual Analogue Scale

Clinical Evidence


Native CT-II™ to treat patients with osteoarthritis: Unpublished study

70 test subjects consumed either 10mg or 40mg of Native CT-II™ for 90 days. Researchers recorded their WOMAC and VAS³ scale scores after day 30, 60 and 90. Results showed that the group taking 40mg of Native CT-II™ had a higher decrease in their WOMAC and VAS scores, which shows that Native CT-II™ is an effective treatment for knee arthritis and joint pain.






Mean VAS score after duration day:




Researchers also measured knee flexion in test subjects and found that taking 40mg of Native CT-II™ was more efficient than 10mg for improving knee flexion in patients with knee arthritis.





Undenatured Type II collagen¹:

Supporting studies show that Undenatured Type II collagen is more effective in assisting joint health and treating joint pain than glucosamine and chondroitin.

Over a 180 day study, researchers measured volunteers' knee osteoarthritis symptoms on the WOMAC scale. Subjects taking 40mg of Undenatured Type II collagen showed a significantly reduced WOMAC score compared to groups taking 1500mg of Glucosamine and 1200mg of Chondroitin, and placebos.







Lipa Pharamaceuticals began in 1995 as a small family business with a firm belief that our success could only be measured by the growth and success of our customers.

We are now **Australia's first choice for complementary medicines manufacturing** and have won Seven prestigious Manufacturer of the Year awards by the sectors Industry Association – Complementary Medicines Australia.

As a contract manufacturer for Australia's biggest vitamin brands, our extensive services offer full supply chain management from product concept to market launch. This includes but is not limited to Product Development, Regulatory and Compliance Support, Research and Development, Quality Management, Stability Programs, Manufacturing and Packaging Solutions.

INGREDIENT

Native CT-II™

RECOMMENDED DAILY DOSE

40mg a day

TARGETS

- Osteoarthritis
- Joint Pain
- Joint Health
- Joint Flexibility

CONTAINS

Undenatured Type II collagen

APPLICATION

- Tablets
- Capsules
- Softgels



ADDRESS

21 Reaghs Farm Rd, Minto NSW, Australia 2566

TEL+61 2 8796 1400 **MAIL** info@Lipa.com.au

WEB www.Lipa.com.au

The above information is confidential, proprietary, and/or the intellectual property of Lipa Pharmaceuticals Australia Pty Ld. It may be neither transferred nor copied to any third party without the prior written consent of Lipa Pharmaceuticals or its subsidiary or affiliated companies. Disclaimer: Lipa Pharmaceuticals Australia Pty Ltd, nor its employees, accepts liability for any information provided that is not supported by The Therapeutic Goods Administration or other relevant regulatory agencies. While reasonable care has been taken to ensure that the information provided herein is accurate, this document is not an authoritative statement under the rules and regulations of the Therapeutic Goods Administration or other regulatory bodies.